Syndax Pharmaceuticals Inc Q3 FY2026 earnings call

• Commercial Momentum: Revuforge demonstrated double-digit quarter-over-quarter growth across key demand metrics, with new patient starts increasing ~20% QoQ to ~300 patients. Prescription volume doubled compared to Q3 2025.
• Transplant Dynamics: A significant operational shift is observed where patients pause treatment for stem cell transplants, creating a short-term headwind but a long-term tailwind as ~60% of KMT2A and ~50% of NPM1 patients resume therapy post-transplant, extending average duration of therapy.
• Market Leadership: Revuforge maintains dominant share of all menin inhibitor starts across all age groups, supported by formulary coverage for nearly 100% of covered lives and an expanding prescriber base of over 620 accounts.
• Pipeline Advancement: The company is advancing toward being the first to launch a menin inhibitor in the frontline setting for newly diagnosed AML. Pipeline assets SNDX-4321 (EGFR inhibitor for NSCLC) and SNDX-62122 (menin inhibitor for myelofibrosis) are on track to enter clinical trials next year.
• Leadership Transition: CFO Keith Goldan retired after four years; Aaron Andre joins as new CFO effective November 9, 2026.

Total revenue reached $83.3 million, up 82% year-over-year. Revuforge (Revumenib) net revenue was $60.7 million, representing approximately 73% of total revenue and reflecting robust market leadership in relapsed/refractory NPM1 and KMT2A acute leukemia. Nick Timbo (Axatilimab) collaboration revenue contributed $22.6 million to Syndax’s bottom line, derived from a 50% share of the product's net sales which totaled $67 million; this represents approximately 27% of total company revenue.

• Full Year Expenses: Guidance for total R&D plus SG&A expenses for 2026 remains at approximately $400 million, excluding $50 million in estimated non-cash stock compensation expense.
• Revenue Outlook: Management expects continued revenue growth from both Revuforge and Nick Timbo, moving the company decisively toward profitability.
• Collaboration Margin: The Nick Timbo margin contribution is expected to settle in the low-to-mid 30% range going forward, up from the previously guided 25-30% range.
• Cash Position: Ended Q3 with $551 million in cash, equivalents, and investments, providing full funding for commercial execution and R&D priorities including pivotal frontline trials.

• Competitive Landscape: Potential registration-enabling data from competitors (e.g., J&J, Sumitomo) may emerge at upcoming meetings, though management asserts Revuforge’s established experience and efficacy profile provide a strong defensive moat.
• Clinical Trial Execution: Pivotal frontline trials (Evolve 2 and Reveal) face risks related to enrollment timelines and endpoint maturity, although management expresses high confidence in study design and execution.
• Regulatory/Approval Uncertainty: Frontline approval pathways depend on complex endpoints like Event-Free Survival (EFS) and MRD-negative CR, which require longer follow-up periods to mature.
• Operational Dependency: Heavy reliance on successful transplant bridging and post-transplant maintenance adherence to drive durable franchise growth; any disruption in these clinical practices could impact revenue trajectories.

Q: Analysts asked about the durability of the rising transplant rates in NPM1 patients (now ~40%) and whether combination use drives deeper responses or just transplant eligibility. / A: Management clarified that treating patients earlier and in combination leads to higher response rates, enabling more patients to bridge to transplant. They noted that while clinical trial data showed lower transplant rates, real-world usage sees higher eligibility due to improved physician comfort and patient fitness. This creates a 'tailwind' effect as patients resume therapy post-transplant, potentially sustaining treatment for 1-2 years.

Q: Questions were raised regarding the competitive threat from potential Phase 2 data from J&J and Sumitomo at ASH, and how Revuforge compares. / A: CEO Michael Metzger stated they reserve judgment until data is public but emphasized Revuforge has a three-year head start and best-in-class efficacy. CMO Dr. Nick Botwood added that their frontline Phase 3 studies are already active and well-executed, leveraging extensive prior data to optimize trial designs, giving them confidence despite competitor entry.

Q: Analysts inquired about the timing of the inflection point where post-transplant resumption becomes a major growth driver for Revuforge. / A: Management explained that because patients pause treatment for 2-5 months during transplant recovery, the revenue impact lags. They expect the greatest positive impact from stacking post-transplant patients to begin materializing in 2027, particularly as both KMT2A and NPM1 populations show similar resumption trends.

Q: Queries focused on the rationale behind delaying Axatilimab Phase 3 top-line results to Q1 2027 and the significance of reduced-frequency dosing data. / A: CMO Dr. Nick Botwood explained the delay allows for presentation of a mature dataset including event-free survival, not just response rates. He highlighted that reduced-frequency dosing (every 4 weeks vs. every 2 weeks) is feasible, well-tolerated, and reduces healthcare burden, potentially informing future labeling and guidelines.